|Quest Diagnostics Announces LeukoVantage™, Advancing Precision Medicine ...|
... of treatment for myeloid neoplasms, a group of hematologic malignancies that includes acute myeloid leukemia (AML), the most common form of adult acute leukemia, as well as myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs).
MarketWatch - Mon, 04 May 2015 09:52
|Quest Diagnostics Announces LeukoVantage(TM), Advancing Precision ...|
Stockhouse - Mon, 04 May 2015 09:52
|Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a ...|
"The clinical activity that we have seen with cerdulatinib in this hematologic cancer study is particularly notable given that these patients have advanced disease and have failed previous therapies," said Manish Patel, M.D., an investigator in the ...
GlobeNewswire (press release) - Fri, 29 May 2015 05:00
|A novel antibody–drug conjugate targeting SAIL for the treatment of ...|
Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin's lymphoma. Here we describe the ...
Nature.com - Fri, 29 May 2015 06:18
|TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the ...|
Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4 inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in ...
GlobeNewswire (press release) - Fri, 29 May 2015 05:22
|ASCO 2015: Karyopharm Therapeutics Solid Tumor Optionality Undervalued ...|
Grade 3/4 toxicities are limited to hematologic and constitutional (fatigue, anorexia, nausea) with the former being more frequent in patients with hematologic malignancies and the later in solid tumors. This leads us to believe that the drug has a ...
Nasdaq - Fri, 29 May 2015 06:58
|Stock Update (NYSEMKT:ATNM): Actinium Pharmaceuticals Inc Clinical Update ...|
Dr. Jurcic is Director of the Hematologic Malignancies Section of the Hematology/Oncology Division and Professor of Clinical Medicine at Columbia University Medical Center. He is a hematologist/oncologist focusing on the treatment of acute and chronic ...
Smarter Analyst - Fri, 29 May 2015 11:49
|Tuesday's Active Stocks: Vale S.A. (NYSE:VALE), American Airlines Group Inc ...|
wsnewspublishers - Wed, 27 May 2015 05:44
|Amgen (AMGN) Announces Presentation on Treatment Of Blood Cancers at EHA|
The data reinforce Amgen's commitment to advancing the care of patients with hematologic malignancies through the development of novel treatment approaches and continued evaluation of marketed products. "We focus on blood cancers that have high ...
StreetInsider.com - Wed, 27 May 2015 13:05
|Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall ...|
Treatment-related adverse events were low in severity with Opdivo and occurred less frequently (any grade:69%)(grade 3–4:10%) than docetaxel (any grade:88%)(grade 3–4:54%), including both hematologic and non-hematologic toxicities. Treatment-related ...
MarketWatch - Fri, 29 May 2015 11:00
|Cookies on Pharmiweb.Com|
PharmiWeb.com (press release) - Fri, 29 May 2015 11:00